Management of acute renal dysfunction in sepsis

Current Infectious Disease Reports

Volumn 14, Issue 5, 2012, Pages 462-473

  Nalesso, Federico ^a,c   Ricci, Zaccaria ^a,b,c   Ronco, Claudio ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^c IRRIV   (Italy)

Author keywords

Acute kidney injury (AKI); Acute lung injury (ALI); Acute respiratory distress syndrome (ARDS); Compensated anti inflammatory response syndrome (CARS); Continuous renal replacement therapy (CRRT); Coupled plasma filtration adsorption (CPFA); CVVH; Early goal directed therapy (EGDT); HFD; High cutoff membranes; High volume hemofiltration (HVHF); Multiple organ dysfunction syndrome (MODS); Peak concentration hypothesis; Renal replacement therapy (RRT); Sepsis; Sepsis related acute kidney injury; Systemic inflammatory response syndrome (SIRS)

Indexed keywords

ADENOSINE A2A RECEPTOR AGONIST; ALPHA INTERMEDIN; ATRIAL NATRIURETIC FACTOR; CASPASE INHIBITOR; DROTRECOGIN; ENDOTHELIN RECEPTOR ANTAGONIST; FENOLDOPAM; FIBRIC ACID DERIVATIVE; FUROSEMIDE; INTERLEUKIN 10; LOOP DIURETIC AGENT; MINOCYCLINE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIFITHRIN ALPHA; PLACEBO; POLYMYXIN B; RECOMBINANT SCATTER FACTOR; RECOMBINANT SOMATOMEDIN C; SPHINGOSINE 1 PHOSPHATE;

ACUTE KIDNEY FAILURE; CONTINUOUS HEMODIALYSIS; CONTINUOUS HEMOFILTRATION; CRYSTALLOID; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG MECHANISM; EARLY DIAGNOSIS; EARLY INTERVENTION; FLUID THERAPY; HEMADSORPTION; HOMEOSTASIS; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; INTENSIVE CARE; INTENSIVE CARE UNIT; INTERVENTION STUDY; PROPHYLAXIS; RENAL PROTECTION; REVIEW; SEPSIS;

EID: 84870554256     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-012-0274-4     Document Type: Review

References (81)

1. Fry DE. Sepsis, systemic inflammatory response, and multiple organ dysfunction: the mystery continues. Am Surg. 2012;78:1-8.
2. Parikh A, Shaw A. The economics of renal failure and kidney disease in critically ill patients. Crit Care Clin. 2012;28:99-111.
3. Oppert M, Engel C, Brunkhorst FM, et al. Acute renal failure in patients with severe sepsis and septic shock-A significant independent risk factor for mortality: results from the German Prevalence Study. Nephrol Dial Transplant. 2008;23:904-9.
4. Kellum JA, Levin N, Bouman C, Lameire N. Developing a consensus classification system for acute renal failure. Curr Opin Crit Care. 2002;8:509-14.
5. Bellomo R, Kellum JA, Ronco C. Defining and classifying acute renal failure: from advocacy to consensus and validation of the RIFLE criteria. Intensive Care Med. 2007;33:409-13.
6. Uchino S, Bellomo R, Goldsmith D, et al. An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med. 2006;34:1913-7.
7. Bagshaw SM, George C, Dinu I, Bellomo R. A multi-centre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients. Nephrol Dial Transplant. October 25, 2007.
8. Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D, Kellum JA. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care. 2006;10:R73.
9. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. Chest. 1992;101:1644-55.
10. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, LeGall JR, Morris A, Spragg R. Report of the American-European Consensus conference on acute respiratory distress syndrome: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Consensus Committee. J Crit Care. 1994;9:72-81.
11. Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney Int. 2008;73 (5):538-46.
12. Bellomo R, Wan L, May C. Managing septic acute renal failure: "fill and spill"? "squeeze and diurese"? or "block Bax to the max"? Crit Care Resusc. 2004;6:12-6.
13. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348:138-50.
14. Ronco C, Tetta C, Mariano F, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs. 2003;27:792-801.
15. Liangos O, Perianayagam MC, Vaidya VS, et al. Urinary N-Acetylbeta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol. 2007;18:904-12.
16. Haase M, Devarajan P, Haase-Fielitz A, et al. The outcome of neutrophil gelatinase-Associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol. 2011;57:1752-61. This paper highlights the role of N-GAL in the early diagnosis of AKI.
17. Liangos O. Drugs and AKI. Minerva Urol Nefrol. 2012;64:51-62.
18. Hilton AK, Bellomo R. A critique of fluid bolus resuscitation in severe sepsis. Crit Care. 2012;16:302.
19. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36:296-327.
20. SAFE Study Investigators. Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med. 2011;37:86-96. This paper is important since it provides very important information about the fluids theraphy of sepsis.
21. Friedman G, Jankowski S, Shahla M, Gomez J, Vincent JL. Hemodynamic effect of 6% and 10% hydroxyethyl starch solutions versus 4% albumin solution in septic patients. J Clin Anesth. 2008;20:528-33.
22. Fang ZX, Li YF, Zhou XQ, Zhang Z, Zhang JS, Xia HM, Xing GP, Shu WP, Shen L, Yin GQ. Effects of resuscitation with crystalloud fluids on cardiac function in patients with severe sepsis. BMC Infect Dis. 2008;8:50.
23. Hartog CS, Brunkhorst FM, Engel C, et al. Are renal adverse effects of hydroxyethyl starches merely a consequence of their incorrect use? Wien Klin Wochenschr. 2011;123:145-55.
24. Dart AB, Mutter TC, Ruth CA, Taback SP. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev. 2010;20:CD007594.
25. Rivers E, Nguyen B, Havstad S, et al. Early Goal-Directed Therapy Collaborative Group: early goal directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368-77.
26. Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med. 1995;333:1025-32.
27. Di Giantomasso D, May CN, Bellomo R. Norepinephrine and vital organ blood flow during experimental hyperdynamic sepsis. Intensive Care Med. 2003;29:1774-81.
28. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358:877-87.
29. Gordon AC, Russell JA, Walley KR, et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med. 2010;36:83-91.
30. Morelli A, Ricci Z, Bellomo R, et al. Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebocontrolled pilot trial. Crit Care Med. 2005;33:2451-6.
31. Lentini P, de Cal M, Clementi A, et al. Sepsis and AKI in ICU Patients: The Role of Plasma Biomarkers. Crit Care Res Pract. 2012;2012:856401. This paper is important since provide some important informations about some interesting biomarkers to early diagnose AKI.
32. Goldstein SL. Acute kidney injury biomarkers: renal angina and the need for a renal troponin I. BMC Med. 2011;9:135.
33. Bellomo R. How to feed patients with renal dysfunction. Blood Purif. 2002;20:296-303.
34. Lipcsey M, Bellomo R. Septic acute kidney injury: hemodynamic syndrome, inflammatory disorder, or both? Crit Care. 2011;15:1008.
35. Langenberg C, Bellomo R, May C, Wan L, Egi M, Morgera S. Renal blood flow in sepsis. Crit Care. 2005;9:R363-74.
36. Ishikawa K, Bellomo R, May CN. The impact of intrarenal nitric oxide synthase inhibition on renal blood flow and function in mild and severe hyperdynamic sepsis. Crit Care Med. 2011;39:770-6.
37. Benes J, Chvojka J, Sykora R, Radej J, Krouzecky A, Novak I, Matejovic M. Searching for mechanisms that matter in early septic acute kidney injury: an experimental study. Crit Care. 2011;15: R256.
38. Ricci Z, Polito A, Polito A, Ronco C. The implications and management of septic acute kidney injury. Nat Rev Nephrol. 2011;7:218-25. This paper hightlights the management of AKI in septic patients and provide important information for the treatments of sepsis related kidney injury.
39. Mehta RL, Pascual MT, Soroko S, Chertow GM, PICARD Study Group. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA. 2002;288:2547-53.
40. Grams ME, Estrella MM, Coresh J, Brower RG, Liu KD. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network. Fluid balance, diuretic use, and mortality in acute kidney injury. Clin J Am Soc Nephrol. 2011;6:966-73.
41. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354:2564-75.
42. Bagshaw SM, Gibney RT, McAlister FA, Bellomo R. The SPARK Study: a phase II randomized blinded controlled trial of the effect of furosemide in critically ill patients with early acute kidney injury. Trials. 2010;11:50.
43. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebocontrolled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet. 2000;356:2139-43.
44. Hirschberg R, Kopple J, Lipsett P, et al. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int. 1999;55:2423-32.
45. Mitka M. Drug for severe sepsis is withdrawn from market, fails to reduce mortality. JAMA. 2011;306:2439-40.
46. Jo SK, Rosner MH, Okusa MD. Pharmacologic treatment of acute kidney injury: why drugs haven't worked and what is on the horizon. Clin J Am Soc Nephrol. 2007;2:356-65.
47. Pickkers P, Heemskerk S, Schouten J, et al. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Crit Care. 2012;16:R14.
48. Gotloib L, Barzilay E, Shustak A, Lev A. Sequential hemofiltration in nonoliguric high capillary permeability pulmonary edema of severe sepsis: preliminary report. Crit Care Med. 1984;12:997-1000.
49. De Vriese AS, Colardyn FA, Philippe JJ, et al. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol. 1999;10:846-53.
50. De Vriese AS, Vanholder RC, Pascual M, et al. Can inflammatory cytokines be removed efficiently by continuous renal replacement therapies? Intensive Care Med. 1999;25:903-10.
51. Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet. 2000;356:26-30.
52. Huang H, Yao T, Wang W, et al. Continuous ultrafiltration attenuates the pulmonary injury that follows open heart surgery with cardiopulmonary bypass. Ann Thorac Surg. 2003;76:136-40.
53. Davenport A. Renal replacement therapy in the patient with acute brain injury. Am J Kidney Dis. 2001;37:457-66.
54. Yekebas EF, Eisenberger CF, Ohnesorge H, et al. Attenuation of sepsis-related immunoparalysis by continuous veno-venous hemofiltration in experimental porcine pancreatitis. Crit Care Med. 2001;29:1423-30.
55. Righetti M, Ferrario GM, Milani S, et al. A single centre study about the effects of HFR on anemia. G Ital Nefrol. 2004;21 Suppl 30:S168-71.
56. Tarakcioglu M, Erbagci AB, Usalan C, et al. Acute effect of hemodialysis on serum levels of the proinflammatory cytokines. Mediat Inflamm. 2003;12:15-9.
57. Fiaccadori E, Maggiore U, Parenti E, et al. Sustained lowefficiency dialysis (SLED) with prostacyclin in critically ill patients with acute renal failure. Nephrol Dial Transplant. 2007;22:529-37.
58. Marshall MR, Golper TA, Shaver MJ, et al. Urea kinetics during sustained low-efficiency dialysis in critically ill patients requiring renal replacement therapy. Am J Kidney Dis. 2002;39:556-70.
59. Van Biesen W, Veys N, Vanholder R. Intermittent hemodialysis for renal replacement therapy in intensive care: new evidence for old truths. Contrib Nephrol. 2007;156:304-8.
60. Lonnemann G, Bechstein M, Linnenweber S, et al. Tumor necrosis factor-Alpha during continuous high-flux hemodialysis in sepsis with acute renal failure. Kidney Int Suppl. 1999;(72):S84-S87.
61. Brunet S, Leblanc M, Geadah D, et al. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis. 1999;34:486-92.
62. Bouman CS, Oudemans-van Straaten HM, et al. Hemofiltration in sepsis and systemic inflammatory response syndrome: the role of dosing and timing. J Crit Care. 2007;22:1-12.
63. Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet. 2000;356:26-30.
64. Cruz DN, Bellomo R, Ronco C. Clinical effects of polymyxin B-immobilized fiber column in septic patients. Contrib Nephrol. 2007;156:444-51.
65. Cruz DN, Perazella MA, Bellomo R, et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007;11:R47.
66. Antonelli M, Fumagalli R, Cruz DN, EUPHAS Study Group, et al. PMX endotoxin removal in the clinical practice: results from the EUPHAS trial. Contrib Nephrol. 2010;167:83-90. Epub 2010 Jun 1. This paper highlight the role of PMX in endotoxin removal and the interesting results in using this device to treat patients with Sepsis from Gram negative bacteria.
67. Uchino S, Bellomo R, Goldsmith D, et al. A new technique for cytokine removal. Intensive Care Med. 2002;28:651-5.
68. Lee PA, Weger GW, Pryor RW, Matson Jr. Effects of filter pore size on efficacy of continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine. Crit Care Med. 1998;26:730-7.
69. Morgera S, Haase M, Rocktaschel J, et al. High permeability haemofiltration improves peripheral blood mononuclear cell proliferation in septic patients with acute renal failure. Nephrol Dial Transplant. 2003;18:2570-6.
70. Morgera S, Haase M, Kuss T, et al. Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure. Crit Care Med. 2006;34:2099-104.
71. Haase M, Bellomo R, Baldwin I, et al. Hemodialysis membrane with a high-molecular-weight cutoff and cytokine levels in sepsis complicated by acute renal failure: a phase 1 randomized trial. Am J Kidney Dis. 2007;50:296-304.
72. Peng ZY, Kiss JE, Cortese-Hasset A, et al. Plasma filtration on mediators of thrombotic microangiopathy: an in vitro study. Int J Artif Organs. 2007;30:401-6.
73. Formica M, Inguaggiato P, Bainotti S, Wratten ML. Coupled plasma filtration adsorption. Contrib Nephrol. 2007;156:405-10.
74. Bellomo R, Tetta C, Ronco C. Coupled plasma filtration adsorption. Intensive Care Med. 2003;29:1222-8.
75. Ronco C, Brendolan A, Lonnemann G, et al. A pilot study of coupled plasma filtration with adsorption in septic shock. Crit Care Med. 2002;30:1250-5.
76. Uchino S, Bellomo R, Morimatsu H, et al. A worldwide practice survey -The Beginning and Ending Supportive Therapy for the Kidney (B.E.S.T. Kidney) Investigators. Intensive Care Med. 2007;33:1563-70.
77. Uchino S, Bellomo R, Kellum JA, et al. Beginning and Ending Supportive Therapy for the Kidney (B.E.S.T. Kidney) Investigators Writing Committee: patient and kidney survival by dialysis modality in critically ill patients with acute kidney injury. Int J Artif Organs. 2007;30:281-92.
78. Van Wert R, Friedrich JO, Scales DC, University of Toronto Acute Kidney Injury Research Group, et al. High-dose renal replacement therapy for acute kidney injury: systematic review and metaanalysis. Crit Care Med. 2010;38:1360-9.
79. RENAL Study Investigators, Bellomo R, Cass A, Cole L, et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high-dose versus standard-dose hemofiltration in acute renalfailure. Blood Purif. 2008;26(5):407-16. Review.
80. Uchino S, Bellomo R, Morimatsu H, et al. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intensive Care Med. 2007;33(9):1563-70.
81. van der Poll T, Opal SM. Host-pathogen interactions in sepsis. Lancet Infect Dis. 2008;8:32-43.